How do we transform cutting-edge scientific discoveries into life-saving diagnostics?
On Diagnosing Dx, we explore the scientific innovation driving diagnostics forward, unpack industry challenges, and spotlight success stories. Join us as we speak with leading researchers and innovators at the forefront of Dx.
Learn to:
🔹 Navigate industry challenges
🔹 Understand emerging science
🔹 Strategise for growth
🔹 Gain future-focused insight
Essential listening for everyone involved in bringing new sciences to life in the Dx and Omics industry, Subscribe now!
Could a 10-Minute Test Stop Unnecessary Antibiotic Prescribing? Paul Kase, CCO - Lumos Diagnostics
In this episode of Diagnosing Dx, David Filby is joined by Paul Kase, Chief Commercial Officer at Lumos Diagnostics.
Paul brings 30 years of healthcare experience, including more than 20 years in rapid point-of-care diagnostics. His history with FebriDx stretches back to its earliest development, and he now leads commercialisation as Lumos enters a major new phase following its US CLIA waiver.
Paul explains how FebriDx uses two host-response biomarkers to help differentiate bacterial from non-bacterial infections from a finger-stick blood sample in around 10 minutes, without instrumentation.
We also discuss antibiotic stewardship, reimbursement, integrating novel tests into existing clinical workflows, and the commercial strategy Lumos is using to drive adoption across urgent care and primary care.
Key takeaways:
🔹 Why the CLIA waiver represents such an important commercial milestone for FebriDx
🔹 How CRP and MxA are used to differentiate bacterial from non-bacterial infection
🔹 Why overlapping respiratory symptoms can contribute to unnecessary antibiotic prescribing
🔹 The three pillars Paul believes every novel point-of-care diagnostic needs to address
🔹 How Lumos is approaching reimbursement, distribution and adoption in the US
Chapters:
01:07 Introduction and Paul Kase’s background
05:43 Lumos Diagnostics and the FebriDx CLIA waiver
08:03 How FebriDx works and the unmet need
09:54 Changing the respiratory testing workflow
14:27 Clinical utility, workflow and reimbursement
20:21 Commercialisation, adoption and distribution
25:14 International expansion and future markets
30:53 Future milestones and driving commercial growth
Guest: Paul Kase
Chief Commercial Officer, Lumos Diagnostics
LinkedIn: https://www.linkedin.com/in/paul-kase-8bb96159/ (https://www.linkedin.com/in/paul-kase-8bb96159/)
Host: David Filby
Founder and CEO of Elevra Consulting
LinkedIn: https://www.linkedin.com/in/davidfilby/ (https://www.linkedin.com/in/davidfilby/)
🔔 Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of diagnostics and omics.
29 Sept 2026
Will Payer-Dependent Diagnostics Companies Get Left Behind? Marty Keiser, Founder at IVBH / Mammogen
In this episode of Diagnosing Dx, David Filby is joined by Marty Keiser, Founder and CEO of IVBH.
After beginning his career in asset management and capital markets, Marty moved into biotech eight years ago with a focus on blood-based molecular diagnostics and early disease detection. That outside perspective shaped how he built IVBH, borrowing ideas from industries beyond diagnostics to create a different model for developing and scaling diagnostic companies.
Marty explains IVBH’s studio model, the science behind its cell-free RNA platform, and how its health franchises are developing tests across breast cancer, lung cancer and metabolic liver disease.
We also discuss why traditional diagnostics business models can struggle, the growing opportunity for cash-pay and consumerised testing, and what helped Mammogen secure institutional Series A funding in a difficult market.
Key takeaways:
🔹 Why Marty believes the traditional diagnostics business model needs to evolve
🔹 How IVBH uses a central discovery platform to build multiple health franchises
🔹 Why cell-free RNA could offer advantages for earlier disease detection
🔹 How LDTs, cash-pay models and new diagnostic “storefronts” could reshape commercialisation
🔹 What investors looked for when Mammogen raised its Series A
Chapters:
01:02 Introduction and Marty Keiser’s background
03:22 Moving from capital markets into diagnostics
08:20 Building the IVBH business model differently
11:27 Surviving the biotech downturn and changing capital markets
16:09 The science behind IVBH’s cell-free RNA platform
20:06 LDTs, cash-pay testing and new commercial models
26:13 What helped Mammogen secure its Series A
30:26 Future milestones and rethinking diagnostics growth
Guest: Marty Keiser
Founder & CEO, IVBH
LinkedIn: https://www.linkedin.com/in/martykeiser (https://www.linkedin.com/in/martykeiser?utm_source=chatgpt.com)
Host: David Filby
Founder and CEO of Elevra Consulting
LinkedIn: https://www.linkedin.com/in/davidfilby/ (https://www.linkedin.com/in/davidfilby/)
🔔 Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of diagnostics and omics.
23 Sept 2026
What If the Patients Who Need Your Test Are Already Hiding in the EHR? Sagacity Diagnostics
In this episode of Diagnosing Dx, David Filby is joined by Raymond Tarr, Founder of Sagacity Diagnostics.
Raymond brings more than 25 years of experience across diagnostics, rare disease, commercialisation and patient finding, with previous roles spanning companies including Cepheid and AstraZeneca/Alexion. His experience in rare disease, both professionally and personally, ultimately led to the creation of Sagacity Diagnostics and its PathfindEHR platform.
Raymond explains how PathfindEHR is designed to help clinicians identify patients who may be undiagnosed, misdiagnosed or missing the right testing by making better use of data already sitting within electronic health records.
We also discuss the adoption challenge facing diagnostics companies, how better workflow integration could drive more appropriate testing, and why education and awareness can be just as important as developing the test itself.
Key takeaways:
🔹 Why existing EHR data could help shorten the diagnostic journey
🔹 How PathfindEHR helps identify suspect and potentially misdiagnosed patients
🔹 Why better workflow integration can increase appropriate diagnostic testing
🔹 How diagnostics companies can benefit from stronger clinician education and adoption tools
🔹 Why rare disease is only the starting point for Sagacity’s wider ambitions
Chapters:
00:59 Introduction and Raymond Tarr’s background
05:46 Moving from diagnostics into rare disease
08:57 The personal experience behind Sagacity Diagnostics
11:00 How PathfindEHR works
17:49 Using EHR data to identify patients who need testing
23:16 How diagnostics companies can benefit from the platform
29:16 Commercialisation and early market traction
34:40 Future milestones and scaling Sagacity
Guest: Raymond Tarr
Founder, Sagacity Diagnostics
LinkedIn: https://www.linkedin.com/in/raymondtarr/ (https://www.linkedin.com/in/raymondtarr/)
Host: David Filby
Founder and CEO of Elevra Consulting
LinkedIn: https://www.linkedin.com/in/davidfilby/ (https://www.linkedin.com/in/davidfilby/)
🔔 Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of diagnostics and omics.
Reach and audience
Public platform figures. Ratings count people who left a rating, not total listeners.
Apple Podcasts (US)
5.0 / 5
1 ratings
Contact Diagnosing Dx
Guest appearances
Books guests
Based on episode analysis; this does not confirm that the show is currently accepting guests.
Host of Diagnosing Dx?
Claim your podcast to manage its listing and keep your show details accurate.
Pod Engine is an independent podcast discovery and analytics service and is not affiliated with or endorsed by this podcast. Artwork and show content belong to their owners. Full legal notice.
Explore this show Podcast research with Pod Engine
